ArticleTranslational lung cancer research2025
Incidence and risk factors of pneumonitis in ALK-rearranged non-small cell lung cancer patients treated with alectinib and thoracic radiotherapy.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma.Clinical case reports · 2026Article
- Predictors of radiation pneumonitis after postoperative radiotherapy in completely resected pathologic stage III-N2 non-small cell lung cancer: a secondary analysis of a prospective cohort.Translational lung cancer research · 2026Article
- Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study.Translational lung cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alectinib and thoracic radiotherapy (TRT) are important modalities in the management of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), both of which can cause treatment-related pneumonitis (TRP), a serious adverse effect. We therefore aimed to assess the incidence and risk factors of TRP, when these two treatments were combined and to guide the medical decisions. Methods: Patients with ALK-rearranged NSCLC, receiving alectinib and TRT from January 2018 to December 2023 were reviewed, and the clinical and dosimetric data were collected. Logistic regression analyses were performed to evaluate risk factors associated with TRP. The prediction ability of dosimetric parameters for TRP was examined by receiver-operating characteristic (ROC) curve analyses. Results: Of the 62 enrolled patients, 39 (62.9%) developed TRP, and 22 (35.5%) developed grade 2 or higher TRP. Logistic regression analyses revealed age [odds ratio (OR) =1.103, 95% confidence interval (CI): 1.027-1.185, P=0.007], tumor location (OR =0.170, 95% CI: 0.035-0.816, P=0.03), duration of alectinib use (OR =1.006, 95% CI: 1.002-1.011, P=0.006), and total lung V30 (OR =1.149, 95% CI: 1.040-1.269, P=0.006) to be risk factors for TRP. After developing TRP, 35 patients recovered or improved, but one patient died due to respiratory failure. Conclusions: The combined use of alectinib and TRT significantly increased the risk of TRP. Clinicians should consider the elevated risks and related dosimetric factors when deciding on combination treatment for ALK-rearranged NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.